Alnylam Earnings Call Highlights TTR-Fueled Breakout

Alnylam Pharmaceuticals ((ALNY)) has held its Q1 earnings call. Read on for the main highlights of the call.

Alnylam Pharmaceuticals delivered an upbeat earnings call, underscoring a breakout quarter with record product sales, strong TTR franchise momentum, and sustained profitability. Management balanced this optimism with candid discussion of royalty-driven margin pressure, heavier R&D and SG&A spending, and localized pricing and phasing headwinds, but reiterated confidence in guidance and long-term strategy.

Record Quarterly Product Revenues

Alnylam crossed a key milestone with combined net product revenues of $1.036 billion in Q1 2026, marking its first-ever quarter above the $1 billion mark. Sales rose 121% year over year and 4% sequentially versus Q4 2025, providing a solid base for the company’s ambitious full‑year revenue targets and reinforcing the commercial strength of its RNAi medicines.

TTR Franchise Momentum

The TTR franchise remained the growth engine, generating $910 million in global net revenues, up 153% year over year and 6% quarter over quarter. In the U.S., TTR revenues jumped about 9% versus Q4 and more than 230% year over year, with $59 million sequential growth despite seasonal shipping and reauthorization hurdles that typically weigh on first‑quarter results.

Strong Rare Disease and Royalty Performance

Beyond TTR, rare disease products posted net revenues of $126 million, an increase of 15% versus the prior year, showing durable demand in these specialized niches. Royalty revenues nearly doubled to $49 million, up 85% year over year, driven largely by rising global sales of LEQVIO and adding a diversified, high-margin income stream to the P&L.

Profitability and Cash Position

Non‑GAAP operating income surged to $339 million, more than quadruple last year’s level, marking the third straight quarter of both GAAP and non‑GAAP profitability. The balance sheet remained solid with $3.0 billion in cash, cash equivalents and marketable securities, up from $2.9 billion at year‑end 2025, giving the company ample firepower to fund its pipeline and launches.

Pipeline Progress and Clinical Momentum

Management highlighted a deep and expanding pipeline, now spanning more than 25 clinical programs across multiple therapeutic areas. Key updates included the start of a Phase I trial for adipose‑directed RNAi candidate ALN‑2232, impactful vutrisiran and zilebesiran data presented at a major cardiology meeting, and accelerated enrollment in the Phase III nucresiran TRITON‑CM trial, which expanded its protocol from about 1,250 to 1,750 patients.

Real-World Evidence Supporting Vutrisiran

Real‑world data over roughly four years showed adherence to vutrisiran above 93% when measured as at least 80% of days covered, and persistence rates exceeding 85% beyond one year, reinforcing its profile in everyday practice. Post‑hoc analyses from the HELIOS‑B study indicated vutrisiran reduced worsening diastolic dysfunction and lowered all‑cause mortality and cardiovascular events regardless of baseline cardiac status.

Commercial Execution and Prescriber Expansion

Commercial execution remained a standout, with more than 1,200 unique new U.S. prescribers added since last March, signaling widening physician adoption. The company reported AMVUTTRA adherence above 90% and first‑line access exceeding 90%, with most patients facing no out‑of‑pocket cost, while international reimbursement wins supported new launches in key European markets and strong performance in Japan.

Reiterated 2026 Guidance and Strategic Vision

Alnylam reaffirmed its 2026 outlook, including TTR product sales of $4.4–$4.7 billion, and emphasized expectations for stronger quarter‑over‑quarter TTR growth through year‑end. Management reiterated its 2030 strategy to deliver at least two transformative medicines beyond TTR, expand RNAi delivery to 10 or more tissue types, grow the clinical portfolio to over 40 programs, and consistently reinvest about 30% of revenues into non‑GAAP R&D.

Gross Margin Pressure from Royalties

Profitability tailwinds were partly offset by gross margin compression, with product gross margin at 80% versus 85% a year ago. The decline stems mainly from rising average royalty rates owed to Sanofi on AMVUTTRA as sales scale and from an annual rate reset, and management warned that margins will likely face continued pressure as TTR volumes expand.

Rising Operating Investments

Operating expenses climbed sharply as the company leaned into growth, with non‑GAAP R&D reaching $335 million, up 39% year over year, reflecting heavy funding of multiple Phase III programs and early‑stage assets. Non‑GAAP SG&A grew 36% to $283 million as Alnylam invests in global launches and commercial infrastructure, a strategy that increases leverage risk if revenue momentum were to slow.

International Pricing Headwind in Germany

Ex‑U.S. TTR revenues slipped by $7 million sequentially, driven mainly by an anticipated price adjustment in Germany associated with the ATTR‑CM launch. Management framed this as a localized and expected headwind and argued that rising cardiomyopathy patient volumes should ultimately offset initial price reductions, but the adjustment weighed on first‑quarter international growth.

Quarterly Phasing and Access Headwinds

The quarter also absorbed typical seasonal and operational factors, including U.S. insurance reauthorization dynamics that can temporarily delay prescriptions and refills. Additionally, a calendar‑driven quirk with fewer shipping and recognition weeks contributed to softer Q1 comparisons, implying the need for stronger sequential growth in later quarters to stay on track with full‑year guidance.

Collaboration Revenue Volatility

Collaboration revenue came in at $82 million, down 17% from the prior year, largely because Q1 2025 included a one‑time $30 million milestone payment. Management emphasized that such milestones can create noise in period‑to‑period comparisons, underscoring that the company’s growth story is increasingly centered on its own product revenues rather than external collaboration timing.

Competitive and Market Uncertainties

Executives also acknowledged looming competitive and market variables, including future data readouts from rival TTR programs and evolving dynamics around established therapies that could affect pricing and treatment patterns. While Alnylam stressed confidence in the durability of its TTR fundamentals and potential combination use, investors were reminded that the broader cardiomyopathy market remains in flux.

Forward-Looking Guidance and Outlook

Looking ahead, Alnylam expects significantly higher quarter‑over‑quarter TTR revenue growth for the rest of 2026 to reach its $4.4–$4.7 billion sales target, building on the $910 million TTR base reported in Q1. Management projects sustained profitability despite an 80% product gross margin and rising royalty burden, while continuing to fund R&D and SG&A growth from a $3.0 billion cash position and emphasizing that Q1 timing headwinds should normalize as the year progresses.

Alnylam’s latest earnings call painted the picture of a company transitioning from emerging biotech to scaled biopharma, powered by a booming TTR franchise and deepening pipeline. While margin pressure, rising investment, and competitive questions remain, management’s reaffirmed guidance and execution track record suggest investors will focus on whether the company can sustain its growth curve through 2026 and beyond.